Trial Profile
A Phase I/II, Non-randomized, Multi-center, Dose-escalating, Two-stage Efficacy and Feasibility Study of the Combination of Everolimus and Capecitabine in Patients With Advanced Malignancies.
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Everolimus (Primary)
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Mar 2010 New trial record